NEW YORK (Reuters) - A surge in sales of pricey new cholesterol treatments is unlikely to materialize this year, contrary to the previous expectations of Express Scripts Holding, an executive from the largest manager of U.S. drug benefits said on Friday.
http://ift.tt/xePdMM
from Reuters: Health News
via
animenewspro
Aucun commentaire:
Enregistrer un commentaire